REPL Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending October 5, 2

SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogn

A chronology of Replimune's RP1 regulatory disclosures alleges that between October 20, 2025 and Apr

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has bee

LOS ANGELES, Sept. 16, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors t

Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency

Squarepoint Ops LLC purchased a new stake in Replimune Group, Inc. (NASDAQ: REPL) during the undefin

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has

LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Replimune Group, Inc.,

Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO

Replimune Group, Inc. (REPL) Shareholder/Analyst Call Prepared Remarks Transcript

Investors allege Replimune Group, Inc. built its RP1 regulatory strategy around single-arm trial des

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogn

Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the E

New York, New York--(Newsfile Corp. - September 11, 2026) - Bronstein, Gewirtz & Grossman, LLC, a na

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered L

Levi and Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securi

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP alerts investors in Replimune Group, Inc. (NASDAQ:

New York, New York--(Newsfile Corp. - September 10, 2026) - Bronstein, Gewirtz and Grossman, LLC, a

JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raise

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.72) per share which beat the analyst

The aggregate gross proceeds from the offering are expected to be approximately $150 million, before

Wedbush analyst Robert Driscoll upgrades Replimune Group (NASDAQ:REPL) from Neutral to Outperform

FDA grants Replimune accelerated approval for TUDRIQEV in combination with nivolumab to treat advanc

Replimune Group, Inc. (NASDAQ:REPL), a commercial stage biotechnology company pioneering the develop

Analysts upgraded Replimune, Madrigal, BBB Foods, Palantir, and Fomento Economico. See other opinion

Leerink Partners analyst Jonathan Chang upgrades Replimune Group (NASDAQ:REPL) from Market Perfor

Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular sessio

FDA advisory panel backed Replimune's RP1 melanoma data ahead of the agency's August 2 decis

US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon sh

Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises

Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-

Top Wall Street analysts upgraded IP, AXTI, REPL, and PLXS stocks with higher price targets. See wha

AMZN: 13% | Amazon.com shares are trading higher after the company reported better-than-expected Q2

Amazon reported strong Q2 results, beating revenue and earnings estimates. Shares jumped 11.9% in pr

https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-panel-backs-replimune-skin-cancer

Replimune shares fall after FDA briefing documents questioned RP1 trial data for advanced melanoma a

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se

Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-

Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 28.6% to $0.64 during Thursday's after-

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Wall Street analysts changed outlook on top names. Wedbush raised Replimune's price target, Cana

Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ:REPL) with a Neutral and raises

Replimune Group (NASDAQ:REPL) reported quarterly losses of $(0.76) per share which missed the analys

Capricor stock falls after the FDA schedules a July advisory committee meeting for Deramiocel, its D

Replimune Group, Inc. (NASDAQ:REPL), a clinical-stage biotechnology company pioneering the developme

FDA reverses its rejection of Regenxbio Navsunli, allowing the company to refile its gene therapy ap

Several stocks, including Optimum Communications Services, surged while Dow fell. Technology, energy

Replimune Group (REPL) shares gain on key RP2 & RP1 oncology data presentations at ASCO. Read th